Payment overview · 2025
General Payments
$468.26
24 reported records · 10 companies
Healthcare provider profile · identity verified
Karol L Davis, MD
Allopathic & Osteopathic Physicians|Family Medicine · KANSAS CITY, KS · NPI 1679531891
Verified facts
What the public records show
CMS Open Payments records show Karol L Davis, MD received $468.26 in general payments during 2025 across 24 reported records.
Astellas Pharma US Inc accounted for 30.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 20 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Synthroid by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Myrbetriq by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 63 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Mounjaro by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $140.65 | 30.0% | 6 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $80.75 | 17.2% | 5 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $55.93 | 11.9% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $45.63 | 9.7% | 3 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $42.46 | 9.1% | 2 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $35.88 | 7.7% | 1 | 2025 |
| Recor Medical Inc | Unresolved — no canonical attribution shown | $21.78 | 4.7% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $15.84 | 3.4% | 1 | 2025 |
| Hologic Sales and Service, LLC | Unresolved — no canonical attribution shown | $15.64 | 3.3% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $13.70 | 2.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $468.26 | 24 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $140.65 | 6 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $80.75 | 5 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $66.14 | 4 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $55.93 | 3 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $55.93 | 3 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $42.46 | 2 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $35.88 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $31.28 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $31.28 | 2 | 2025 |
Source payment records
|
|||||
| Paradise Ultrasound Renal Denervation System Normalized: paradise ultrasound renal denervation system |
Device | Recor Medical Inc | $21.78 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $15.84 | 1 | 2025 |
Source payment records
|
|||||
| APTIMA Normalized: aptima |
Device | Hologic Sales and Service, LLC | $15.64 | 1 | 2025 |
Source payment records
|
|||||
| THINPREP 2000 PROCESSOR Normalized: thinprep 2000 processor |
Device | Hologic Sales and Service, LLC | $15.64 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $14.35 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $14.35 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $13.70 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $13.70 | 1 | 2025 |
Source payment records
|
|||||
| ROTATEQ Normalized: rotateq |
Biological | Merck Sharp & Dohme LLC | $13.70 | 1 | 2025 |
Source payment records
|
|||||
| VAXELIS Normalized: vaxelis |
Biological | Merck Sharp & Dohme LLC | $13.70 | 1 | 2025 |
Source payment records
|
|||||
| VAXNEUVANCE Normalized: vaxneuvance |
Biological | Merck Sharp & Dohme LLC | $13.70 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 18 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
63 | 18 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 545 | 154 |
| Amlodipine Besylate | Amlodipine Besylate | 357 | 97 |
| Levothyroxine Sodium | Levothyroxine Sodium | 300 | 78 |
| Lisinopril | Lisinopril | 292 | 84 |
| Losartan Potassium | Losartan Potassium | 281 | 79 |
| Omeprazole | Omeprazole | 237 | 54 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 231 | 70 |
| Hydrochlorothiazide | Hydrochlorothiazide | 192 | 56 |
| Duloxetine Hcl | Duloxetine Hcl | 183 | 36 |
| Gabapentin | Gabapentin | 168 | 45 |
| Escitalopram Oxalate | Escitalopram Oxalate | 130 | 32 |
| Metformin Hcl | Metformin Hcl | 128 | 37 |
| Metformin Hcl Er | Metformin Hcl | 126 | 37 |
| Simvastatin | Simvastatin | 121 | 25 |
| Tramadol Hcl | Tramadol Hcl | 112 | 27 |
| Metoprolol Succinate | Metoprolol Succinate | 95 | 30 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 93 | 26 |
| Pantoprazole Sodium | Pantoprazole Sodium | 92 | 28 |
| Ezetimibe | Ezetimibe | 91 | 30 |
| Sertraline Hcl | Sertraline Hcl | 87 | 24 |
| Metoprolol Tartrate | Metoprolol Tartrate | 86 | 24 |
| Famotidine | Famotidine | 80 | 24 |
| Meloxicam | Meloxicam | 78 | 19 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 76 | 19 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 76 | 16 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 73 | 24 |
| Alendronate Sodium | Alendronate Sodium | 64 | 23 |
| Jardiance | Empagliflozin | 63 | 18 |
| Carvedilol | Carvedilol | 60 | 15 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 59 | 27 |
| Potassium Chloride | Potassium Chloride | 58 | 22 |
| Rybelsus | Semaglutide | 53 | suppressed |
| Alprazolam | Alprazolam | 51 | 17 |
| Glipizide Er | Glipizide | 51 | 13 |
| Fluoxetine Hcl | Fluoxetine Hcl | 49 | 14 |
| Ozempic | Semaglutide | 47 | 11 |
| Zolpidem Tartrate | Zolpidem Tartrate | 46 | 11 |
| Clopidogrel | Clopidogrel Bisulfate | 45 | 14 |
| Furosemide | Furosemide | 43 | 15 |
| Tamsulosin Hcl | Tamsulosin Hcl | 42 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 40 | 16 |
| Allopurinol | Allopurinol | 39 | 13 |
| Bupropion Xl | Bupropion Hcl | 37 | suppressed |
| Clonazepam | Clonazepam | 36 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 36 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 36 | 12 |
| Atenolol | Atenolol | 35 | 11 |
| Eliquis | Apixaban | 35 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 34 | 12 |
| Sumatriptan Succinate | Sumatriptan Succinate | 34 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 31 | suppressed |
| Spironolactone | Spironolactone | 30 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 29 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 27 | 15 |
| Celecoxib | Celecoxib | 26 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 25 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 25 | suppressed |
| Lovastatin | Lovastatin | 24 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 24 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 23 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 23 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 20 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 20 | suppressed |
| Glimepiride | Glimepiride | 20 | suppressed |
| Mirtazapine | Mirtazapine | 20 | suppressed |
| Synthroid | Levothyroxine Sodium | 20 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 19 | suppressed |
| Myrbetriq | Mirabegron | 19 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 19 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 19 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 18 | suppressed |
| Mounjaro | Tirzepatide | 18 | suppressed |
| Acyclovir | Acyclovir | 17 | suppressed |
| Prednisone | Prednisone | 17 | 15 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 17 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 17 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 16 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 16 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 16 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 14 | 13 |
| Temazepam | Temazepam | 14 | suppressed |
| Xarelto | Rivaroxaban | 14 | suppressed |
| Cephalexin | Cephalexin | 13 | 13 |
| Telmisartan | Telmisartan | 13 | suppressed |
| Chlordiazepoxide Hcl | Chlordiazepoxide Hcl | 12 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 12 | suppressed |
| Estradiol | Estradiol | 11 | suppressed |
| Invokana | Canagliflozin | 11 | suppressed |
| Lorazepam | Lorazepam | 11 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 11 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 11 | suppressed |
| Valsartan | Valsartan | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $468.26 · 24 records | Astellas Pharma US Inc | APTIMA, CAPVAXIVE, EVENITY, FREESTYLE LIBRE 3, GARDASIL 9, LEQVIO, MOUNJARO, OTEZLA, PROLIA, Paradise Ultrasound Renal Denervation System, QULIPTA, REPATHA, ROTATEQ, THINPREP 2000 PROCESSOR, TZIELD, UBRELVY, VAXELIS, VAXNEUVANCE, Veozah, ZEPBOUND | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error